Kenya is among nine African countries, under the low- and middle-income category, that are set to be among the early beneficiaries of lenacapavir, a long-acting HIV prevention drug, following a recent Global Fund deal.
According to the Division of National AIDS and STI Control Program, the drug, which is expected to be in the country by January 2026, will play a key role in thrusting the country towards its ultimate goal of eliminating HIV/AIDs by 2030.
In a statement on Monday, July 9, Global Fund confirmed that it had penned an agreement with Gilead Sciences, a US-based pharmaceutical, which is the manufacturer of the drug, that will allow over 120 low- and middle-income countries (LMICs) to access the drug.
This will mark the first time in history that an HIV prevention drug is introduced to these countries at the same time as in high-income countries.
